VJOncology is committed to improving our service to you

ASCO 2020 | ARCHES post-hoc analyses: efficacy of ENZA + ADT in mHSPC by pattern of metastatic spread

VJOncology is committed to improving our service to you

Neal Shore

Neal Shore, MD, Carolina Urologic Research Center, Myrtle Beach, SC, discusses the post-hoc analyses of the ARCHES trial (NCT02677896), which investigated androgen deprivation therapy (ADT) with enzalutamide (ENZA) or a placebo in metastatic hormone-sensitive prostate cancer (mHSPC). The post-hoc analyses assessed how the pattern of metastatic spread impacts the efficacy of ENZA + ADT in mHSPC patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter